Bladder Neoplasm
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
We examined potential mechanisms of FOXA1 and PTEN inactivation in bladder cancer and their contribution to tumor heterogeneity.
|
31636388 |
2020 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, it was suggested MEG3 can interact with miR-494 to regulate PTEN in bladder cancer development.
|
31294463 |
2020 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this context, PIK3CA, p-AKT and nuclear PTEN could be used along with other biomarkers for prognosis and selection of appropriate therapy in the clinical management of bladder cancer.
|
30941989 |
2019 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
We confirmed the oncogenic role of METTL3 in bladder cancer by accelerating the maturation of pri-miR221/222, resulting in the reduction of PTEN, which ultimately leads to the proliferation of bladder cancer.
|
31228940 |
2019 |
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our present study reveals that USP13 functions as a tumor suppressor by interacting with PTEN protein and increasing its expression in bladder cancer.
|
31200745 |
2019 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our data support that nuclear PTMA protein serves as a tumor suppressor in bladder cancer through upregulating PTEN and orchestrating TRIM21 for the regulation of Nrf2 signaling.
|
30719818 |
2019 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Nevertheless, the PTEN-specific inhibitor significantly abolished the mGluR4 activation-induced cell apoptosis and proliferative inhibition in bladder cancer cell lines.
|
30145816 |
2019 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mechanistically, circSLC8A1 could directly interact with miR-130b/miR-494, and subsequently act as a miRNA sponge to regulate the expression of the miR-130b/miR-494 target gene PTEN and downstream signaling pathway, which suppressed the progression of bladder cancer.
|
31228937 |
2019 |
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we aimed to explore whether Jarid2 could interact with H3K27me3 to regulate PTEN expression in bladder cancer.
|
31125562 |
2019 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Transfection of miR-34a mimics upregulated the expression of phosphatase and tensin homolog (PTEN) in bladder cancer cells, and decreased cell migration and invasion. miR-34a may inhibit bladder cancer cell migration and invasion by upregulating PTEN. miR-34a may additionally serve as a potential therapeutic target for bladder cancer.
|
31612063 |
2019 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
circ-ITCH acts as a tumor suppressor by a novel circ-ITCH/miR-17, miR-224/p21, PTEN axis, which may provide a potential biomarker and therapeutic target for the management of BCa.
|
29386015 |
2018 |
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The results showed that phosphatase and tensin homolog deleted on chromosome ten (PTEN) was downregulated and phosphorylated-AKT (pAKT) was overexpressed in human bladder cancer.
|
30333873 |
2018 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Lentiviral vectors that contained the tumor suppressor genes, p53, p16, and PTEN, were transfected into human bladder cancer cell lines, 5637, T24, 253J, and UMUC3, and the normal human uroepithelial cell line, SV-HUC-1.
|
29599318 |
2018 |
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Taken together, we first demonstrated that RP11-79H23.3 might suppress the pathogenesis and development of BC by acting as a sponge for miR-107 to increase PTEN expression.
|
30149689 |
2018 |
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We utilized polymerase chain reaction (PCR) to access PTEN expression in bladder cancer and adjacent tissues.
|
29917188 |
2018 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
S473 phosphorylation was not controlled by uPAR in bladder cancer cell lines that are PTEN-negative; however, this result probably did not reflect altered mTORC2 regulation.
|
27777073 |
2017 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Overall, these findings indicate that miR-495 upregulation contributes to bladder cancer cell growth, invasion, and tumorigenesis by targeting PTEN and offer a potential therapeutic target for bladder cancer.
|
28069380 |
2017 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that the miR-130b-3p/PTEN/integrin β1 axis could play a critical role in the progression and development of BC and that miR-130b-3p might be a valuable clinical marker and therapeutical target for BC patients.
|
28042869 |
2016 |
Bladder Neoplasm
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In addition, we observed that bladder cancer cell lines (RT4, UMUC-3, and J82) with homozygous deletion of either TSC1 or PTEN are more sensitive to metformin than those (TEU2, TCCSUP, and HT1376) with wild-type TSC1 and PTEN genes.
|
26921394 |
2016 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Taken together, EN2 may be a candidate oncogene in BC by activating the PI3K/Akt pathway and inhibiting PTEN, and may be a potential therapeutic target for the treatment of BC.
|
25812440 |
2015 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
The oncogenic role of miR19a in bladder cancer was dependent on targeting PTEN.
|
25107371 |
2014 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
PTEN is linked to aggressive tumour phenotype and to unfavourable outcome in early bladder cancer.Heterozygous PTEN loss, i.e. reduced PTEN gene dosage, might be sufficient to cause aggressive tumour behaviour in bladder cancer cells.
|
24004025 |
2013 |
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24.
|
20857258 |
2011 |
Bladder Neoplasm
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We found a significant correlation between the expression of PTEN, Cx-26 and L-plastin with known clinically important pathologic features of bladder cancer (tumor grade, stage, and growth pattern).
|
18288642 |
2008 |
Bladder Neoplasm
|
0.300 |
Biomarker
|
disease |
BEFREE |
Frequent mutations or deletions of PTEN (phosphatase and tensin homolog deleted on chromosome 10) are reported in bladder cancer, while there are few studies which evaluated PTEN as a clinical prognostic parameter of superficial bladder cancer.
|
18480628 |
2008 |